Moreover, in LIHC cohort, PHF19 was closely correlated with checkpoints including BTLA, CD27, CD274, CD276, CD28, CD40, CD70, CD80, CD86, CTLA4, HAVCR2, HHLA2, ICOS, IDO1, LAG3, PDCD1, TIGIT, TNFRSF9, and TNFSF9, indicating that PHF19 serves as a potential immune-related therapeutic target for HCC patients. This evidence concerns the gene BTLA and hepatocellular carcinoma.